Logo image of IMUC

IMMUNOCELLULAR THERAPEUTICS (IMUC) Stock Price, Forecast & Analysis

USA - NYSE Arca - NYSEARCA:IMUC - US4525362046

0.053
-0.17 (-75.91%)
Last: 10/16/2018, 8:13:46 PM

IMUC Key Statistics, Chart & Performance

Key Statistics
Market Cap2.22M
Revenue(TTM)N/A
Net Income(TTM)-6.11M
Shares41.94M
Float40.68M
52 Week High0.55
52 Week Low0.03
Yearly Dividend0
Dividend Yield0%
EPS(TTM)-1.45
PEN/A
Fwd PEN/A
Earnings (Next)N/A
IPON/A
Sector
GICS SectorN/A
GICS IndustryN/A
GICS IndustryGroupN/A
GICS SubIndustryN/A
IMUC short term performance overview.The bars show the price performance of IMUC in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60

IMUC long term performance overview.The bars show the price performance of IMUC in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of IMUC is 0.053 null. In the past month the price decreased by -74.76%. In the past year, price decreased by -86.75%.

IMMUNOCELLULAR THERAPEUTICS / IMUC Daily stock chart

IMUC Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

IMUC Fundamental Analysis

ChartMill assigns a fundamental rating of 2 / 10 to IMUC. IMUC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMUC Financial Highlights

Over the last trailing twelve months IMUC reported a non-GAAP Earnings per Share(EPS) of -1.4500000000000002. The EPS increased by 86.7% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -159.47%
ROE -178.18%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%99.02%
Sales Q2Q%N/A
EPS 1Y (TTM)86.7%
Revenue 1Y (TTM)N/A

IMUC Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next Y-100%
Revenue Next YearN/A

IMUC Ownership

Ownership
Inst Owners4.29%
Ins Owners1.01%
Short Float %0%
Short Ratio0

About IMUC

Company Profile

ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.

Company Info

IMMUNOCELLULAR THERAPEUTICS

23622 CALABASAS ROAD SUITE 300

CALABASAS CA 91302

CEO: Anthony Gringeri

Phone: 818-264-2300

IMMUNOCELLULAR THERAPEUTICS / IMUC FAQ

What does IMUC do?

ImmunoCellular Therapeutics, Ltd. operates as a development stage company with primary focus on the development and commercialization of new therapeutics to fight cancer using the immune system. Its product candidate portfolio includes cellular immunotherapies targeting cancer and cancer stem cell antigens, peptide based immunotherapies targeting cancer stem cells, and monoclonal antibodies to diagnose and treat several different cancers. ImmunoCellular Therapeutics, Ltd. is based in California, USA.


Can you provide the latest stock price for IMMUNOCELLULAR THERAPEUTICS?

The current stock price of IMUC is 0.053 null. The price decreased by -75.91% in the last trading session.


What is the dividend status of IMMUNOCELLULAR THERAPEUTICS?

IMUC does not pay a dividend.


How is the ChartMill rating for IMMUNOCELLULAR THERAPEUTICS?

IMUC has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.


Where is IMMUNOCELLULAR THERAPEUTICS (IMUC) stock traded?

IMUC stock is listed on the NYSE Arca exchange.


Is IMMUNOCELLULAR THERAPEUTICS (IMUC) stock a good buy?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on IMUC.